Healthcare >> Analyst Interviews >> October 21, 2016
Investing in Best-in-Class Emerging Pharmaceuticals
Liana Moussatos, Ph.D. is a Managing Director and Senior Research Analyst at Wedbush Securities. She joined Wedbush Securities from Pacific Growth Equities, where she was a Senior Research Analyst. Prior to that Dr. Moussatos came from UBS Global Asset Management where she was Director and Portfolio Manager of the UBS Global Biotech Funds. Previously, she was with Bristol-Meyers Squibb where she was a Manager in university and government licensing, external science and technology, and she also worked with Sloan-Kettering Cancer Institute in the Office of Industrial Affairs and the National Cancer Institute in the Office of Technology Development. Dr. Moussatos received a B.S. in entomology and an M.S. in zoology and biochemistry from Clemson University. She also earned a Ph.D. in plant pathology from the University of California, Davis, and completed a postdoctoral research fellowship in cellular and molecular physiology at the Yale School of Medicine. Profile
TWST: Can you give a broad description of your coverage?
Dr. Moussatos: We call it emerging pharmaceuticals, and basically I look at what I consider to be